By Fineline Cube Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) announced receiving tacit clinical approval from China’s National Medical Products Administration (NMPA) for JY47, a SIRPα‑targeted monoclonal antibody, enabling initiation of clinical trials in metabolic dysfunction‑associated steatohepatitis (MASH) with liver fibrosis – a novel immunometabolic approach to the growing non‑alcoholic steatohepatitis therapeutic market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Tacit clinical approval (IND clearance) |
| Product | JY47 – SIRPα‑targeted monoclonal antibody |
| Company | Hangzhou Jiuyuan Gene Engineering Co., Ltd. (HKG: 2566) |
| Indication | Metabolic dysfunction‑associated steatohepatitis (MASH) with liver fibrosis |
| Novelty | First SIRPα‑targeted therapy entering MASH clinical development |
Drug Profile & Mechanism of Action
- Molecule: JY47 – SIRPα (signal regulatory protein alpha)‑targeted monoclonal antibody
- Target Biology:
- SIRPα – inhibitory receptor binding with high affinity to ligand CD47
- CD47‑SIRPα signaling – critical pathway in immune regulation related to metabolic diseases
- Therapeutic Hypothesis:
- SIRPα antagonism modulates immune cell function
- Improves tissue microenvironment and metabolic homeostasis
- Addresses MASH pathophysiology through immunometabolic mechanism vs. traditional metabolic or antifibrotic approaches
- Preclinical Validation:
- Promising therapeutic potential demonstrated in in vitro organoid models
- Efficacy confirmed in in vivo MASH disease models
Scientific Context & Strategic Positioning
| Dimension | Current MASH Landscape | JY47 Position |
|---|---|---|
| Approved Therapies | Resmetirom (THR‑β agonist) – first FDA‑approved March 2024; limited efficacy in fibrosis | Novel immunometabolic mechanism distinct from metabolic (THR‑β, FGF21) and antifibrotic approaches |
| Pipeline Mechanisms | GLP‑1 RA (semaglutide), PPAR agonists, ASK1 inhibitors, CCR2/5 antagonists | First‑in‑class SIRPα targeting – immune‑modulatory approach to metabolic disease |
| Fibrosis Focus | Critical unmet need – no approved therapies halt/reverse MASH fibrosis | Targets MASH with liver fibrosis – high‑risk population with limited options |
| CD47/SIRPα Precedent | Magrolimab (CD47 mAb) failed in oncology; SIRPα targeting unexplored in metabolic disease | Differentiated target (SIRPα vs. CD47) may avoid hematologic toxicity while preserving immunomodulatory benefit |
Market Impact & Outlook
- MASH Market Dynamics: Global MASH prevalence estimated at 300+ million patients; addressable pharmaceutical market projected to exceed US$30 billion by 2030 driven by obesity epidemic and diabetes comorbidity; fibrotic MASH (F2‑F4) represents highest‑risk, highest‑value segment with limited therapeutic options.
- Immunometabolic Frontier: JY47 enters clinic as first SIRPα‑targeted therapy in metabolic disease, validating emerging science linking innate immune dysfunction to metabolic disease progression; success would open new drug class for MASH, NASH, and potentially type 2 diabetes with inflammatory components.
- Jiuyuan Pipeline Diversification: JY47 represents expansion beyond company’s established biologics portfolio (recombinant proteins, cytokines) into monoclonal antibody therapeutics and metabolic disease indications; NMPA approval demonstrates regulatory affairs capabilities for novel mechanism submissions.
- Clinical Development Trajectory: Phase I safety/tolerability expected H2 2026‑H1 2027; MASH clinical trials require 12‑24 month treatment duration for histologic endpoints (NASH resolution, fibrosis improvement); Phase IIa proof‑of‑concept data anticipated 2028‑2029 contingent on biomarker strategy and biopsy endpoints.
- Competitive Differentiation: SIRPα mechanism provides differentiation vs. crowded GLP‑1 and THR‑β space; partnership potential with metabolic disease‑focused biotech or large pharma upon Phase I safety demonstration and mechanism validation in human MASH patients.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, therapeutic potential, and market expectations for JY47. Actual results may differ due to risks including safety findings in first‑in‑class mechanism, MASH trial design complexity, and competitive dynamics in the evolving NASH/MASH therapeutic landscape.-Fineline Info & Tech